Common use of SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS Clause in Contracts

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS. This prospectus supplement contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. All statements contained in this prospectus supplement, other than statements of historical fact are forward-looking statements. You should not unduly rely on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, some of which are beyond our control. These risks, uncertainties and other factors may cause our actual results, performance or achievements to be materially different from the anticipated future results, performance or achievements expressed or implied by the forward-looking statements. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, statements relating to: • our integration efforts following the acquisition of Private Viridian (as defined below); • our future research and development activities, including clinical testing and the costs and timing thereof; • our strategy, including clinical development of VRDN-001 and other product candidates, and the clinical and commercial potential of our product candidates, if approved; • the sufficiency of our cash resources; • our ability to raise additional funding when needed; • any statements concerning anticipated regulatory activities or licensing or collaborative arrangements; • business interruptions resulting from the COVID-19 outbreak or similar public health crises, which could cause a disruption in the development of our product candidates and adversely impact our business; • our research and development and other expenses; • our operations and legal risks; • our ability to maintain our listing on a national securities exchange; and • any statement of assumptions underlying any of the foregoing. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from the anticipated future results, performance or achievements expressed or implied by any forward-looking statements, including the factors described under the heading “Risk Factors” in this prospectus supplement and the accompanying prospectus, and the risk factors and cautionary statements described in other documents that we file from time to time with the SEC, specifically under the heading “Item 1A. Risk Factors” and elsewhere in our most recent Annual Report on Form 10-K for the year ended December 31, 2020 that was filed with the SEC on March 26, 2021. You should evaluate all forward-looking statements made in this prospectus supplement and the accompanying prospectus, including the documents we incorporate by reference, in the context of these risks, uncertainties and other factors. We caution you that the risks, uncertainties and other factors referred to above may not contain all of the risks, uncertainties and other factors that are important to you. In addition, we cannot assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. All forward-looking statements in this prospectus supplement and the accompanying prospectus, including the documents we incorporate by reference, apply only as of the date made and are expressly qualified in their entirety by the cautionary statements included in this prospectus supplement and the accompanying prospectus. We undertake no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS. This prospectus supplement contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this prospectus supplement, including statements regarding our future results of operations and financial position, business strategy, product candidates, product pipeline, ongoing and planned clinical studies, including those of our collaboration partners, regulatory approvals, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations are forward-looking statements. Many of the forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided contained in this prospectus supplement can be identified by the Private Securities Litigation Reform Act use of 1995. The forward-looking words such as “anticipate,” “believe,” “maycould,” “willexpect,” “should,” “plan,” “intend,” “estimate,” “continue,will” “anticipate,” “intend,” “plan,” “expect,” “predict,” and “potential,” “opportunity,” “goals,” among others. Forward-looking statements appear in a number of places in this prospectus supplement and include, but are not limited to, statements regarding our intent, belief or “should,” current expectations. Forward-looking statements are based on our management’s beliefs and similar expressions assumptions, and on information currently available to our management. Such statements are intended subject to identify risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements. All statements contained due to various factors, including, but not limited to, those identified under “Risk Factors” in this prospectus supplement. These risks and uncertainties include factors relating to: · the success of our and our collaboration partners’ clinical studies, and our and their ability to obtain and maintain regulatory approval and, if approved, to commercialize our active immunotherapy product candidates (ACI-35.030, ACI-24.060 and ACI-7104.056), monoclonal antibody product candidates (semorinemab and crenezumab) and diagnostic product candidates (Tau-PET tracer PI-2620 and a-syn-PET tracer ACI-12589) and to a lesser extent, our preclinical candidates; · the preclinical and clinical safety, efficacy and utility of our product candidates; · the ability of our competitors to discover, develop or commercialize competing products before or more successfully than we do; · our plans to research, develop and commercialize our product candidates; · the identification of serious adverse, undesirable or unacceptable side effects related to our product candidates; · our ability to maintain our current strategic relationships with our collaboration partners; · our ability to protect and maintain our, and not infringe on third parties’, intellectual property rights throughout the world; · our ability to raise capital when needed in order to continue our product development programs or commercialization efforts; · our ability to attract and retain qualified employees and key personnel; · the acceptance by the Food and Drug Administration (FDA) and applicable foreign regulatory authorities of data from studies that we and our collaboration partners conduct within and outside the U.S. now and in the future; · our foreign private issuer (FPI) status, the loss of which would require us to comply with the Exchange Act’s domestic reporting regime, and cause us to incur significant legal, accounting and other than statements expenses; · our incorporation in Switzerland, the laws of historical fact are forward-looking statements. You should not unduly rely on which govern our corporate affairs and may differ from those applicable to companies incorporated in the U.S.; and · the other risk factors discussed under “Risk Factors.” These forward-looking statements because they involve known speak only as of the date of this prospectus supplement and unknown are subject to a number of risks, uncertainties and other factorsassumptions described under the section in this prospectus supplement entitled “Risk Factors” and elsewhere in this prospectus supplement. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control. These risks, uncertainties and other factors may cause our actual results, performance or achievements to be materially different from the anticipated future results, performance or achievements expressed or implied by the you should not rely on these forward-looking statementsstatements as predictions of future events. Actual The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factorsstatements. Moreover, including, without limitation, statements relating to: • our integration efforts following the acquisition of Private Viridian (as defined below); • our future research and development activities, including clinical testing and the costs and timing thereof; • our strategy, including clinical development of VRDN-001 and other product candidates, and the clinical and commercial potential of our product candidates, if approved; • the sufficiency of our cash resources; • our ability to raise additional funding when needed; • any statements concerning anticipated regulatory activities or licensing or collaborative arrangements; • business interruptions resulting from the COVID-19 outbreak or similar public health crises, which could cause a disruption we operate in the development of our product candidates and adversely impact our business; • our research and development and other expenses; • our operations and legal risks; • our ability to maintain our listing on a national securities exchange; and • any statement of assumptions underlying any of the foregoingan evolving environment. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from the anticipated future results, performance or achievements expressed or implied by any forward-looking statements, including the factors described under the heading “Risk Factors” in this prospectus supplement and the accompanying prospectus, and the New risk factors and cautionary statements described in other documents that we file uncertainties may emerge from time to time with the SECtime, specifically under the heading “Item 1A. Risk Factors” and elsewhere in our most recent Annual Report on Form 10-K it is not possible for the year ended December 31, 2020 that was filed with the SEC on March 26, 2021management to predict all risk factors and uncertainties. You should evaluate all forward-looking statements made in this prospectus supplement and the accompanying prospectus, including the documents we incorporate Except as required by reference, in the context of these risks, uncertainties and other factors. We caution you that the risks, uncertainties and other factors referred to above may not contain all of the risks, uncertainties and other factors that are important to you. In additionapplicable law, we cando not assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. All forward-looking statements in this prospectus supplement and the accompanying prospectus, including the documents we incorporate by reference, apply only as of the date made and are expressly qualified in their entirety by the cautionary statements included in this prospectus supplement and the accompanying prospectus. We undertake no obligation plan to publicly update or revise any forward-looking statements to reflect subsequent events contained herein, whether as a result of any new information, future events, changed circumstances or circumstancesotherwise.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS. This prospectus, each prospectus supplement and the information incorporated by reference in this prospectus and each prospectus supplement contains and may contain certain statements that constitute “forward-looking statements that involve substantial risks and uncertainties for purposes statements” within the meaning of Section 27A of the safe harbor provided by the Private Securities Litigation Reform Act of 19951933 and Section 21E of the Exchange Act. The words “believemay,” “maymight,” “can,” “will,” “estimateto be,” “continuecould,” “anticipatewould,” “should,” “expect,” “intend,” “plan,” “expectobjective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “opportunitylikely,” “goalscontinue” and “ongoing,” or “should,” and similar expressions the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. All Those statements contained appear in this prospectus, any accompanying prospectus supplementsupplement and the documents incorporated herein and therein by reference, other than particularly in the sections entitled “The Company,” “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business,” and include statements regarding the intent, belief or current expectations of historical fact the Company and management that are forward-looking statements. You should not unduly rely on forward-looking statements because they involve subject to known and unknown risks, uncertainties and other factorsassumptions. This prospectus, some any prospectus supplement and the information incorporated by reference in this prospectus and any prospectus supplement also contain statements that are based on the current expectations of which our company and management. You are beyond our control. These risks, uncertainties and other factors may cause our actual results, performance or achievements to be materially different from the anticipated future results, performance or achievements expressed or implied by the cautioned that any such forward-looking statements. Actual statements are not guarantees of future performance and involve risks and uncertainties, and that actual results and performance could may differ materially from those projected in the forward-looking statements as a result of many various factors, including, without limitation, statements relating to: • our integration efforts following the acquisition of Private Viridian (as defined below); • our future research and development activities, including clinical testing and the costs and timing thereof; • our strategy, including clinical development of VRDN-001 and other product candidates, and the clinical and commercial potential of our product candidates, if approved; • the sufficiency of our cash resources; • our ability to raise additional funding when needed; • any statements concerning anticipated regulatory activities or licensing or collaborative arrangements; • business interruptions resulting from the COVID-19 outbreak or similar public health crises, which could cause a disruption in the development of our product candidates and adversely impact our business; • our research and development and other expenses; • our operations and legal risks; • our ability to maintain our listing on a national securities exchange; and • any statement of assumptions underlying any of the foregoing. These Because forward-looking statements involve known are inherently subject to risks and unknown uncertainties, some of which cannot be predicted or quantified, you should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. The risks, uncertainties and other factors assumptions that may could cause our actual results to be differ materially different from the those anticipated future results, performance or achievements expressed or implied by any in our forward-looking statementsstatements include, including the factors described but are not limited to, those set forth above under the heading section entitled “Risk Factors” and in this the applicable prospectus supplement, together with all of the other information contained in or incorporated by reference into the prospectus supplement or appearing or incorporated by reference into this prospectus. Except as required by applicable law, including the securities laws of the United States and the accompanying prospectus, rules and the risk factors and cautionary statements described in other documents that we file from time to time with regulations of the SEC, specifically under the heading “Item 1A. Risk Factors” and elsewhere in our most recent Annual Report on Form 10-K for the year ended December 31, 2020 that was filed with the SEC on March 26, 2021. You should evaluate all forward-looking statements made in this prospectus supplement and the accompanying prospectus, including the documents we incorporate by reference, in the context of these risks, uncertainties and other factors. We caution you that the risks, uncertainties and other factors referred to above may do not contain all of the risks, uncertainties and other factors that are important to you. In addition, we cannot assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. All forward-looking statements in this prospectus supplement and the accompanying prospectus, including the documents we incorporate by reference, apply only as of the date made and are expressly qualified in their entirety by the cautionary statements included in this prospectus supplement and the accompanying prospectus. We undertake no obligation plan to publicly update or revise any forward-looking statements to reflect subsequent contained herein after we distribute this prospectus, whether as a result of any new information, future events or circumstancesotherwise.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS. This prospectus supplement contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and financial position, business strategy, product candidates, product pipeline, ongoing and planned clinical studies, including those of our collaboration partners, regulatory approvals, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations are forward-looking statements. Many of the forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided contained in this prospectus can be identified by the Private Securities Litigation Reform Act use of 1995. The forward-looking words such as “anticipate,” “believe,” “maycould,” “willexpect,” “should,” “plan,” “intend,” “estimate,” “continue,will” “anticipate,” “intend,” “plan,” “expect,” “predict,” and “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forwardamong others. Forward-looking statements. All statements contained appear in a number of places in this prospectus supplementand include, other than but are not limited to, statements of historical fact are forward-looking statementsregarding our intent, belief or current expectations. You should not unduly rely on forwardForward-looking statements because they involve known are based on our management’s beliefs and unknown risksassumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, uncertainties and other factors, some of which are beyond our control. These risks, uncertainties and other factors actual results may cause our actual results, performance or achievements to be materially different from the anticipated future results, performance or achievements expressed or implied by the forward-looking statements. Actual results and performance could differ materially from those projected expressed or implied in the forward-forward- looking statements as a result of many due to various factors, including, without limitationbut not limited to, statements relating to: • our integration efforts following the acquisition of Private Viridian (as defined below); • our future research and development activities, including clinical testing and the costs and timing thereof; • our strategy, including clinical development of VRDN-001 and other product candidates, and the clinical and commercial potential of our product candidates, if approved; • the sufficiency of our cash resources; • our ability to raise additional funding when needed; • any statements concerning anticipated regulatory activities or licensing or collaborative arrangements; • business interruptions resulting from the COVID-19 outbreak or similar public health crises, which could cause a disruption in the development of our product candidates and adversely impact our business; • our research and development and other expenses; • our operations and legal risks; • our ability to maintain our listing on a national securities exchange; and • any statement of assumptions underlying any of the foregoing. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from the anticipated future results, performance or achievements expressed or implied by any forward-looking statements, including the factors described those identified under the heading section entitled “Risk Factors” in this prospectus supplement prospectus. These risks and uncertainties include factors relating to: · the accompanying prospectussuccess of our and our collaboration partners’ clinical studies, and our and their ability to obtain and maintain regulatory approval and to commercialize our active immunotherapies (ACI-35.030, ACI-24.060 and ACI-7104.056), monoclonal antibodies (semorinemab and crenezumab) and diagnostics (Tau-PET tracer PI-2620 and a-syn-PET tracer ACI-12589) and to a lesser extent our preclinical candidates; · the preclinical and clinical safety, efficacy and utility of our product candidates; · the ability of our competitors to discover, develop or commercialize competing products before or more successfully than we do; · our plans to research, develop and commercialize our product candidates; · the identification of serious adverse, undesirable or unacceptable side effects related to our product candidates; · our ability to maintain our current strategic relationships with our collaboration partners; · our ability to protect and maintain our, and not infringe on third parties’, intellectual property rights throughout the world; · our ability to raise capital when needed in order to continue our product development programs or commercialization efforts; · our ability to attract and retain qualified employees and key personnel; · the acceptance by the Food and Drug Administration (FDA) and applicable foreign regulatory authorities of data from studies that we and our collaboration partners conduct within and outside the U.S. now and in the future; · our foreign private issuer (FPI) status, the loss of which would require us to comply with the Exchange Act’s domestic reporting regime, and cause us to incur significant legal, accounting and other expenses; · our incorporation in Switzerland, the laws of which govern our corporate affairs and may differ from those applicable to companies incorporated in the U.S.; and · the other risk factors and cautionary statements described in other documents that we file from time to time with the SEC, specifically under the heading “Item 1A. Risk Factors” and elsewhere discussed in our most recent Annual Report on Form 1020-K F. AC IMMUNE SA AC Immune is a leading, clinical stage biopharmaceutical company advancing one of the broadest portfolios focused on pioneering Precision Medicine for neurodegenerative diseases. Our highly differentiated approach integrates novel therapeutics and diagnostics to overcome the year ended December 31, 2020 that was filed with the SEC on March 26, 2021. You should evaluate all forward-looking statements made fundamental challenge in this prospectus supplement therapeutic area – the high number of co-pathologies driving disease development and progression and the accompanying prospectusurgent need for more tailored therapeutic regimens. Leveraging our dual proprietary technology platforms, including the documents SupraAntigen and Morphomer, we incorporate by referencehave built a comprehensive pipeline of first-in-class or best- in-class candidates spanning multiple treatment modalities and targeting both established and emerging neurodegenerative pathologies. We are currently advancing 16 therapeutic and diagnostic programs, with one in the context a Phase 3 and five in Phase 2 clinical trials, targeting five different types of these risksmisfolded pathological proteins related to Alzheimer’s disease (AD), uncertainties Xxxxxxxxx’x disease (PD) and other factorsneurodegenerative disorders. Our pipeline assets are further validated by the multiple partnerships we have established with leading global pharmaceutical companies. We caution you that believe our clinically validated technology platforms and multi-target, multimodal approach position AC Immune to revolutionize the riskstreatment paradigm for neurodegenerative disease by shifting it towards Precision Medicine and disease prevention. We are a Swiss stock corporation (société anonyme) organized under the laws of Switzerland. We were formed as a Swiss limited liability company (société à responsabilité limitée) on February 13, uncertainties 2003 with our registered office and other factors referred domicile in Basel, Switzerland. We converted to above may not contain all a Swiss stock corporation (société anonyme) under the laws of Switzerland on August 25, 2003. Our Swiss enterprise identification number is CHE-109.878.825. Our domicile and registered office is in Ecublens, at the risksÉcole Polytechnique Fédérale Lausanne (EPFL) Innovation Park Building B, uncertainties 1015 Lausanne, Vaud, Switzerland. Our common shares were admitted to trading on Nasdaq Global Market on September 23, 2016, and other factors that trade under the symbol ACIU. Our registered and principal executive offices are important to youlocated in Ecublens, at EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland, our general telephone number is (00) 00 000 00 00 and our internet address is xxx.xxxxxxxx.xxx. In addition, we cannot assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. All forward-looking statements in this prospectus supplement Our website and the accompanying information contained on or accessible through our website are not part of this prospectus, including the documents we incorporate by reference, apply only as of the date made and are expressly qualified in their entirety by the cautionary statements included in this prospectus supplement and the accompanying prospectus. We undertake no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS. This prospectus supplement contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this prospectus supplement, including statements regarding our future results of operations and financial position, business strategy, product candidates, product pipeline, ongoing and planned clinical studies, including those of our collaboration partners, regulatory approvals, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations are forward-looking statements. Many of the forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided contained in this prospectus supplement can be identified by the Private Securities Litigation Reform Act use of 1995. The forward-looking words such as “anticipate,” “believe,” “maycould,” “willexpect,” “should,” “plan,” “intend,” “estimate,” “continue,will” “anticipate,” “intend,” “plan,” “expect,” “predict,” and “potential,” “opportunity,” “goals,” among others. Forward-looking statements appear in a number of places in this prospectus supplement and include, but are not limited to, statements regarding our intent, belief or “should,” current expectations. Forward-looking statements are based on our management’s beliefs and similar expressions assumptions, and on information currently available to our management. Such statements are intended subject to identify risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements. All statements contained due to various factors, including, but not limited to, those identified under “Risk Factors” in this prospectus supplement. These risks and uncertainties include factors relating to: · the success of our and our collaboration partners’ clinical studies, and our and their ability to obtain and maintain regulatory approval and to commercialize ACI-35, semorinemab, Morphomer Tau, ACI-24 for Alzheimer’s disease (AD) and for Down syndrome-related AD (ACI-24 for DS), crenezumab, and PI-2620, our Tau-positron emission tomography (PET) imaging tracer and to a lesser extent our preclinical candidates; · the preclinical and clinical safety, efficacy and utility of our product candidates; · the ability of our competitors to discover, develop or commercialize competing products before or more successfully than we do; · our plans to research, develop and commercialize our product candidates; · the identification of serious adverse, undesirable or unacceptable side effects related to our product candidates; · our ability to maintain our current strategic relationships with our collaboration partners; · our ability to protect and maintain our, and not infringe on third parties’, intellectual property rights throughout the world; · our ability to raise capital when needed in order to continue our product development programs or commercialization efforts; · our ability to attract and retain qualified employees and key personnel; · the acceptance by the Food and Drug Administration (FDA) and applicable foreign regulatory authorities of data from studies that we and our collaboration partners conduct within and outside the US now and in the future; · our foreign private issuer status, the loss of which would require us to comply with the Exchange Act’s domestic reporting regime, and cause us to incur significant legal, accounting and other than statements expenses; · our incorporation in Switzerland, the laws of historical fact are forward-looking statements. You should not unduly rely on which govern our corporate affairs and may differ from those applicable to companies incorporated in the US; and · The other risk factors discussed under “Risk Factors.” These forward-looking statements because they involve known speak only as of the date of this prospectus supplement and unknown are subject to a number of risks, uncertainties and other factorsassumptions described under the sections in this prospectus supplement entitled “Risk Factors” and elsewhere in this prospectus supplement. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control. These risks, uncertainties and other factors may cause our actual results, performance or achievements to be materially different from the anticipated future results, performance or achievements expressed or implied by the you should not rely on these forward-looking statementsstatements as predictions of future events. Actual The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factorsstatements. Moreover, including, without limitation, statements relating to: • our integration efforts following the acquisition of Private Viridian (as defined below); • our future research and development activities, including clinical testing and the costs and timing thereof; • our strategy, including clinical development of VRDN-001 and other product candidates, and the clinical and commercial potential of our product candidates, if approved; • the sufficiency of our cash resources; • our ability to raise additional funding when needed; • any statements concerning anticipated regulatory activities or licensing or collaborative arrangements; • business interruptions resulting from the COVID-19 outbreak or similar public health crises, which could cause a disruption we operate in the development of our product candidates and adversely impact our business; • our research and development and other expenses; • our operations and legal risks; • our ability to maintain our listing on a national securities exchange; and • any statement of assumptions underlying any of the foregoingan evolving environment. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from the anticipated future results, performance or achievements expressed or implied by any forward-looking statements, including the factors described under the heading “Risk Factors” in this prospectus supplement and the accompanying prospectus, and the New risk factors and cautionary statements described in other documents that we file uncertainties may emerge from time to time such as the global pandemic originating with the SECCovid-19, specifically under the heading “Item 1A. Risk Factors” and elsewhere in our most recent Annual Report on Form 10-K it is not possible for the year ended December 31, 2020 that was filed with the SEC on March 26, 2021management to predict all risk factors and uncertainties. You should evaluate all forward-looking statements made in this prospectus supplement and the accompanying prospectus, including the documents we incorporate Except as required by reference, in the context of these risks, uncertainties and other factors. We caution you that the risks, uncertainties and other factors referred to above may not contain all of the risks, uncertainties and other factors that are important to you. In additionapplicable law, we cando not assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. All forward-looking statements in this prospectus supplement and the accompanying prospectus, including the documents we incorporate by reference, apply only as of the date made and are expressly qualified in their entirety by the cautionary statements included in this prospectus supplement and the accompanying prospectus. We undertake no obligation plan to publicly update or revise any forward-looking statements to reflect subsequent events contained herein, whether as a result of any new information, future events, changed circumstances or circumstances.otherwise. S-v